Guard Therapeutics: Positive Data – MAD Study

Research Note

2020-08-06

13:58

Redeye raises its base and bear case for Guard Therapeutics to 3,3 SEK/share and 1,3 SEK/share respectively. Today, Guard Therapeutics presented positive data from their phase 1 MAD study. The results indicated a good safety profile and good pharmacokinetic properties. Combining these results with previous results from the SAD study and its follow-up, Redeye raises its likelihood of approval.

NF

LS

Nima Faroghi

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.